 This is a two-part safety and efficacy study of SKI-606 in subjects who have Philadelphia chromosome positive leukemias CML. Part 1 will be a dose-escalation study, in which an escalating dose of SKI-606 Bosutinib, up to 600 mg, will be studied in subjects with imatinib resistantrefractory or imatinib intolerant chronic phase CML. Part 2 will evaluate the safety and efficacy of the maximum tolerated dose MTD of SKI-606 Bosutinibidentified in Part 1 of the study. 